Eli Lilly and Novo Nordisk dominate the rapidly expanding weight-loss drug market, yet investors face challenges in assessing their valuations and growth prospects. While Eli Lilly leads the sector, concerns about overvaluation persist, and Novo Nordisk is grappling with clinical setbacks and anticipated revenue declines. Amidst this competitive landscape, Dexcom emerges as a compelling investment alternative, leveraging its continuous glucose monitoring (CGM) devices, which are increasingly prescribed alongside weight-loss treatments.
The relationship between weight-loss drugs and CGM adoption presents a unique opportunity for Dexcom. As more patients seek obesity treatments, they often receive diabetes diagnoses, expanding the addressable market for CGM technology. Notably, studies indicate that CGM usage tends to rise among users of GLP-1 medications, suggesting that Dexcom’s business could thrive alongside the growth of anti-obesity treatments rather than suffer.
For investors, Dexcom’s established market position and competitive advantages make it a safer bet in the weight-loss drug arena. With a significant portion of eligible patients still not utilizing CGM devices, the potential for growth remains substantial, positioning Dexcom for strong returns in the coming years.
Source: fool.com